BioLineRx (BLRX) Cash & Current Investments (2012 - 2025)

BioLineRx's Cash & Current Investments history runs 14 years deep, the most recent figure standing at $20.9 million for Q4 2025.

• In Q4 2025, Cash & Current Investments rose 6.72% year-over-year to $20.9 million; the TTM figure through Dec 2025 stood at $20.9 million (up 6.72% YoY), while the FY2025 annual figure was $20.9 million, up 6.72% from the prior year.
• Cash & Current Investments was $20.9 million for Q4 2025 at BioLineRx, down from $25.2 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $65.6 million in Q2 2021 to a low of $19.6 million in Q4 2024.
• Historically, Cash & Current Investments has averaged $40.3 million across 5 years, with a median of $38.8 million in 2023.
• The sharpest annual moves came in 2021 and 2023: Cash & Current Investments surged 198.67% in 2021, then plunged 54.65% in 2023.
• A 5-year view of Cash & Current Investments shows it stood at $57.1 million in 2021, then decreased by 10.59% to $51.1 million in 2022, then slipped by 15.83% to $43.0 million in 2023, then sank by 54.5% to $19.6 million in 2024, then increased by 6.72% to $20.9 million in 2025.
• The last three Cash & Current Investments figures came in at $20.9 million (Q4 2025), $25.2 million (Q3 2025), and $31.4 million (Q2 2025), per Business Quant data.